Use of ion channel blocker in treatment and / or prevention of hepatic fibrosis

Ion channel blockers, particularly gliclazide, address the inefficacies of current liver fibrosis treatments by inhibiting hepatic stellate cell activation through the autophagy pathway, effectively reducing liver fibrosis markers and proliferation.

JP2024167866AActive Publication Date: 2024-12-04AFFILIATED HOSPITAL OF ZUNYI UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023195477
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-22
Filing Date
2023-11-16
Publication Date
2024-12-04
Estimated Expiration
2043-11-16

AI Technical Summary

Technical Problem

Current anti-fibrosis measures for liver fibrosis, such as antiviral treatment and dietary management, require long treatment periods and have low therapeutic effects with many side effects, and there is a lack of effective therapeutic methods targeting hepatic stellate cells (HSCs) activation.

Method used

The use of ion channel blockers, specifically potassium ion channel blockers like gliclazide, to inhibit hepatic stellate cell activation by suppressing the autophagy pathway, thereby treating and preventing liver fibrosis.

Benefits of technology

Gliclazide effectively suppresses hepatic stellate cell activation, reducing liver fibrosis by downregulating α-SMA expression and inhibiting proliferation, while upregulating the autophagy substrate P62, thus providing a more effective and targeted approach to liver fibrosis treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024167866000001_ABST
    Figure 2024167866000001_ABST
Patent Text Reader

Abstract

To provide drugs for more effective treatment and / or prevention of liver fibrosis.SOLUTION: There is provided, an ion channel blocker in production of drugs for treating and / or preventing liver fibrosis. The ion channel blocker is a potassium ion channel blocker. Specifically, use of gliclazide is provided.SELECTED DRAWING: Figure 2
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the technical field of ion channels and liver fibrosis, and in particular to the use of ion channel blockers in the treatment and / or prevention of liver fibrosis. [Background technology]

[0002] The number of chronic liver disease patients worldwide has reached more than 800 million, of which the number of deaths from various liver diseases reaches 2 million each year. The hepatic fibrosis (HF) stage is not only the common pathological basis of all chronic liver diseases, but also an important part of the progression to liver cirrhosis and liver cancer. Research has shown that liver fibrosis, and even early liver cirrhosis, can be reversed. However, current anti-fibrosis measures are mainly the removal of liver fibrosis etiology through antiviral treatment, abstinence from alcohol, and dietary management, and these measures generally have shortcomings such as long treatment periods, low therapeutic efficacy, many side effects, and low patient compliance. Therefore, we have been searching for a method that can significantly reverse liver fibrosis.

[0003] Currently, hepatic stellate cell (HSC) activation and excessive deposition of hepatic extracellular matrix (ECM) are considered to be important parts of the pathophysiological changes of liver fibrosis. Hepatic stellate cells (HSCs), first discovered by von Kupffer in 1876, reside in the subendothelial space of Disse, located between hepatic sinusoidal endothelial cells (LSECs) and hepatocytes, and they account for approximately 10% of all resident hepatocytes. In normal liver, hepatic stellate cells maintain a non-proliferative, quiescent phenotype. After liver injury or in vitro culture, hepatic stellate cells are activated and transform from vitamin A-storing cells to myofibrillar cells, characterized by proliferation, contraction, inflammation, and chemotaxis, and increased extracellular matrix (ECM) production. HSC activation involves various regulatory mechanisms, including autophagy, endoplasmic reticulum stress, oxidative stress, retinol and cholesterol metabolism, epigenetics, and receptor-mediated signals, demonstrating the complexity of HSC activation. Currently, targeting mechanisms of several important molecular channel disorders that lead to HSC activation, such as transforming growth factor β (TGF-β) and platelet-derived growth factor (PDGF), have been found, and some of the mechanisms involved in HSC activation have already been elucidated. However, unfortunately, to date, there is still a lack of clinical anti-fibrotic therapeutic methods that target HSCs. Therefore, by exploring other pathways that cause HSC activation, it may be possible to find more effective anti-fibrotic therapeutic targets.

[0004] Ion channels have been a hot topic of research in recent years, and some ion channels are thought to play important roles in the development, migration, invasion, and metastasis of gastrointestinal cancers, including gastric cancer and liver cancer. Summary of the Invention

[0005] The object of the present invention is to solve the above-mentioned problems existing in the prior art by providing the use of ion channel blockers in the treatment and / or prevention of liver fibrosis.

[0006] In order to achieve the above object, the present invention provides the following means. The present invention provides the use of an ion channel blocker in the manufacture of a medicament for the treatment and / or prevention of liver fibrosis.

[0007] Preferably, the ion channel blocker is a potassium ion channel blocker.

[0008] Preferably, the potassium ion channel blocker comprises gliclazide.

[0009] Preferably, the liver fibrosis is caused by CCl 4 This includes hepatic fibrosis induced by

[0010] The present invention further provides the use of gliclazide in the manufacture of a medicament for inhibiting autophagy in liver tissue.

[0011] The present invention further provides the use of gliclazide in the manufacture of a medicament for inhibiting the proliferation of hepatic stellate cells.

[0012] Preferably, said hepatic stellate cells comprise HSC-T6 cells.

[0013] The present invention further provides the use of gliclazide in the manufacture of a medicament for downregulating hepatocyte α-SMA.

[0014] The present invention further provides the use of gliclazide in the manufacture of a medicament for downregulating hepatocyte LC3.

[0015] The present invention provides the use of gliclazide in the manufacture of a medicament for upregulating hepatocyte P62.

[0016] The present invention discloses the following technical effects. The present invention is based on the fact that the activation of hepatic stellate cells is an important part of anti-liver fibrosis, and in vivo and in vitro experiments have found that gliclazide has the effect of inhibiting the activation of hepatic stellate cells.Furthermore, it has been found that gliclazide inhibits the activation of hepatic stellate cells mainly by inhibiting the autophagy pathway, and thus gliclazide can be used to manufacture medicines for treating and / or preventing liver fibrosis. [Brief description of the drawings]

[0017] In order to more clearly describe the embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings necessary for the embodiments. Obviously, the drawings described below are only some embodiments of the present invention, and those skilled in the art can obtain other drawings based on these drawings without creative efforts. [Figure 1] FIG. 2 is a diagram showing the degree of fibrosis of liver tissue observed by HE staining and picrosirius red staining in Example 1. [Diagram 2] FIG. 2 shows the changes in serum AST (A) and ALT (B) levels and statistical charts detected in Example 1. [Diagram 3] FIG. 1 shows (A) changes in the expression of α-SMA in liver tissue detected by immunohistochemistry in Example 2, and a statistical diagram (B). [Figure 4] FIG. 1 shows (A) changes in the expression of α-SMA in liver tissue detected by Western blotting in Example 3, and a statistical diagram (B). [Diagram 5] FIG. 1 shows (A) changes in LC3 expression in mouse liver tissue detected by Western blotting in Example 3, and a statistical diagram (B). [Figure 6] FIG. 1 shows (A) changes in expression of P62 in liver tissue detected by Western blotting in Example 3, and a statistical diagram (B). [Figure 7] FIG. 4 is a statistical diagram showing the effect of co-culture of gliclazide and TGF-β1 on HSCs proliferation detected by CCK8 in Example 4. [Figure 8]1 shows (A) changes in the expression levels of α-SMA protein in HSCs cells detected by Western blotting in Example 5, and a statistical diagram (B). [Figure 9] FIG. 13 shows (A) changes in LC3 expression in HSCs cells detected by Western blotting in Example 5, and a statistical diagram (B). [Figure 10] FIG. 1 shows (A) changes in expression of p62 in HSCs cells detected by Western blotting in Example 5, and a statistical diagram (B). [Figure 11] FIG. 13 shows (A) changes in the expression of α-SMA in HSCs cells after the addition of Rapamycin detected by Western blotting in Example 6, and a statistical diagram (B). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] While various exemplary embodiments of the present invention are described in detail, it should be understood that the following detailed description is not intended to limit the invention, but rather to describe in more detail certain aspects, features and embodiments of the present invention.

[0019] The above technical solutions of the present invention are all common solutions in the art unless otherwise stated, and the reagents or raw materials used are all commercially available or existing unless otherwise stated.

[0020] Example 1: Carbon tetrachloride (CCl 4 )-induced liver fibrosis in mice Experimental materials 60 healthy male C57 mice (20-25 g / mouse, purchased from Chongqing Tengxin Biotechnology Co., Ltd.), a gavage needle, a 1 mL syringe, and CCl 4 solution, olive oil, gliclazide solution.

[0021] Experimental Method CCl 4 Solution: CCl 4 Olive oil solution (CCl 4Gliclazide solution: Gliclazide solution was dissolved in saline and prepared at the time of use. The concentration was 500 μM.

[0022] Mice were randomly divided into four groups: A normal control group; b. Model group: Mice were administered CCl 4 The solution was administered by oral gavage at 0.1 mL / 20 g (twice a week for a total of 8 weeks). C.CCl 4 + Glycyst group: Mice were given CCl 4 The solution alone was administered orally at 0.1 mL / 20 g (twice a week for a total of 2 weeks), followed by glybdolyst solution and CCl 4 The solution was co-administered for 6 weeks. The glybdostat solution was administered intraperitoneally once daily at a dose of 0.2 mL / 20 g. d. Gliclazide group: Gliclazide was intraperitoneally injected for 8 weeks, 0.2mL / 20g, once a day.

[0023] The mice were euthanized at 2, 4, 6, and 8 weeks after model establishment, one mouse per group was euthanized each time. Liver samples were removed and flash-frozen in liquid nitrogen at -80℃ for storage, and the other livers were fixed in 4% paraformaldehyde for 24 hours and then embedded in paraffin. The severity of liver fibrosis was observed by appearance, picrosirius red staining, and HE staining. If the staining results showed liver fibrosis, the model was considered to have been successfully established. Then, all mice were euthanized, eyeball blood was collected to measure liver function indexes (ALT, AST), and liver tissues were fixed in formaldehyde and embedded in paraffin for use.

[0024] Experimental Results As shown in Figure 1-2, the results of collecting and detecting eyeball blood from the model group at the 8th week showed that both ALT and AST were significantly elevated. As a result of HE staining, in the normal group, the structure of liver tissue was clear, the structure of liver lobule was normal, the liver cells were intact, and the pattern was clear. In the model group, liver tissue was damaged and fibrous tissue was significantly proliferated. In the carbon tetrachloride + gliclazide group, the degree of liver tissue damage and fibrous tissue proliferation were both significantly reduced. As can be seen from the picrosirius red staining results, in the model group, the red collagen fibers became thicker and longer, and some formed pseudolobules, indicating that the mouse liver fibrosis model was successfully established. In the gliclazide group, no obvious collagen fibers were found, indicating that at a concentration of 500 μm, gliclazide cannot cause liver fibrosis in mice.

[0025] Example 2: Immunohistochemical detection of protein expression levels of α-SMA, an indicator of liver fibrosis among different groups Experimental materials: C57 mice, α-SMA primary antibody, immunohistochemistry kit, PBS solution, sodium citrate solution, etc.

[0026] Experimental method: The paraffin block of Example 1 was taken, and after sectioning, immunohistochemistry was performed according to the procedure. The sections were immersed in 100%, 95%, 80%, and 75% ethanol for 5 minutes, washed with PBS, removed catalase with hydrogen peroxide, repaired antigens with sodium citrate repair solution, cooled and washed with PBS, blocked at room temperature for 30 minutes, added primary antibody, incubated at 4°C overnight, and incubated with secondary antibody at room temperature for 1 hour the next day, stained with DBA, re-stained with hematoxylin, differentiated with hydrochloric acid alcohol, dehydrated, sealed, and finally observed and photographed under a microscope.

[0027] Experimental Results: As shown in Figure 3, gliclazide can down-regulate the expression of α-SMA in carbon tetrachloride-induced liver fibrosis mice.

[0028] Example 3: Detection of the expression status of liver fibrosis indicator α-SMA and autophagy-related indicators (LC3, P62) in different experimental groups by Western blot technique Experimental materials: Mouse liver tissue, tweezers, scissors, 2 mm steel ball, magnet, cell lysis solution, PBS solution, BCA protein quantification kit, skim milk powder, αSMA, LC3 and P62 primary antibodies and corresponding secondary antibodies, etc.

[0029] Experimental method: Take the liver tissue of Example 1, cut out pieces the size of a grain of rice with tweezers and scissors, and add them to a marked 1.5mL EP tube. Put two 2mm steel balls into each EP tube, add 200-250μL of cell lysis solution, set the parameters, put into a grinder and grind thoroughly, then use a magnet to suck out the steel balls, and after working on ice for 30min, centrifuge at 12000rpm, 30min, 4℃. A standard curve was made, and 1μL of protein sample, 19μL of PBS solution, and 200μL of BCA working solution (50:1) were added to each well of a 96-well plate, and two additional wells were added to each well. Placed in a drying oven at 37℃ for 30min. ELISA was used to measure the OD value at 560nm, and the protein concentration was calculated. The protein was boiled in boiling water for 5min, and then the sample was loaded, followed by gel electrophoresis, transfer, and sealing, and then incubated with primary and secondary antibodies and exposed to light.

[0030] Experimental results: As shown in Figures 4-6, gliclazide can significantly reduce the expression of αSMA and LC3 in liver tissue, and significantly increase the expression level of autophagy substrate P62 in liver tissue.

[0031] Example 4: Detection of the effect of co-culture of gliclazide and TGF-β1 on HSCs cell proliferation by CCK8 Experimental materials: HSC-T6 cells, DMEM complete medium, 96-well plate, counting plate, CCK-8 working solution, etc.

[0032] Experimental method: First, HSC-T6 hepatic stellate cells were cultured in DMEM culture medium containing 10% fetal bovine serum, 1% double antibody (penicillin-streptomycin solution), and 1% non-essential amino acids (NEAA) at 37°C and 5% CO. 2 After the cells reached 80%-90% confluence, they were digested with trypsin and passaged. Then, they were seeded on plates at a density of 7 × 10 6 The cell suspension of 100 μL / well was taken and added to a 96-well culture plate at 100 μL / well. There were 6 wells in each group. The experiment was divided into a control group, a TGF-β1 group, and a drug group of TGF-β1 + different concentrations (50 μM, 100 μM, 150 μM, 200 μM) of gliclazide. After the cells attached to the wall, the remaining groups were added with the corresponding concentrations of gliclazide, except for the control group and the TGF-β1 group, and after 3 h, TGFβ1 (10 ng / mL) was added to the corresponding groups to stimulate mouse hepatic stellate cells. After 48 h of incubation, 100 μL of the "10% CCK8 + 90% medium" mixed solution was added to each well, and incubated at 37 °C for 1-4 h. The wavelength was set to 450 nm, and the absorbance value was read and recorded at the corresponding wavelength by a fully automatic microplate reader. The effect of gliclazide on cell proliferation was detected by CCK8 experiments, and the optimal action time point and drug concentration were screened.

[0033] Experimental results: As shown in Figure 7, compared with the normal value, the proliferation of HSC-T6 cells could be significantly induced after stimulation with TGF-β1, and the co-culture with gliclazide and TGF-β1 at concentrations of 100 μM, 150 μM, and 200 μM suppressed the proliferation tendency induced by TGF-β1, and the difference in the results was statistically significant (P<0.05).

[0034] Example 5: Detection of the expression status of α-SMA and autophagy-related indicators (LC3, P62) in HSCs cells by Western blot technique Experimental materials: HSC-T6 cells, DMEM complete medium, cell culture dish, cell lysis solution, PBS solution, BCA protein quantification kit, skim milk powder, αSMA, LC3 and P62 primary antibodies and corresponding secondary antibodies, etc.

[0035] Experimental method: First, the normal group, TGF-β1 group, gliclazide + TGF-β1 group, and gliclazide group were divided into a normal group, a TGF-β1 group, a gliclazide group, and a gliclazide group. Here, the TGF-β1 stimulation concentration was 10 ng / mL, and the gliclazide concentration was 100 μm. HSC-T6 cells were cultured using cell culture dishes, cultured under the conditions described in Example 4, and drugs were added and TGF-β1 was added. After 48 h, the incubated cells were washed 3-4 times with pre-cooled PBS, and then the remaining PBS liquid was aspirated and dried with filter paper, and 50 μL of RIPA and 0.5 μL of 100 mol / L PMSF (100:1) were added to a 50 mL culture flask, and the mixture was allowed to act on ice for 30 minutes, after which the protein was scraped off with a cell scraper, and the protein was aspirated into an EP tube and centrifuged at 12000 rpm, 30 minutes, and 4 ° C. A standard curve was made, and 1 μL of protein sample, 19 μL of PBS, and 200 μL of BCA working solution (50:1) were added to each well of a 96-well plate, and two additional wells were added to each well. The plates were placed in a dry oven at 37°C for 30 min. ELISA was used to measure the OD value at 560 nm, and the protein concentration was calculated. The proteins were boiled in boiling water for 5 minutes before loading the samples, and gel electrophoresis, transfer, and sealing were performed in sequence, and the primary and secondary antibodies were incubated and then exposed to light.

[0036] Experimental results: As shown in Figures 8-10, gliclazide can significantly reduce the expression of αSMA and LC3 in HSCs cells, and significantly increase the expression level of autophagy substrate P62 in HSCs cells.

[0037] Example 6: Detection of α-SMA expression levels in HSCs cells after addition of an autophagy agonist (Rapamycin) by Western blot technique Experimental materials: HSC-T6 cells, Rapamycin, DMEM complete medium, cell culture dish, cell lysis solution, PBS solution, BCA protein quantification kit, skim milk powder, αSMA, LC3 and P62 primary antibodies and corresponding secondary antibodies, etc.

[0038] Experimental method: Similarly, the subjects were first divided into a normal group, a TGF-β1 group, a gliclazide + TGF-β1 group, and a gliclazide + TGF-β1 + Rapamycin group. Here, the TGF-β1 stimulation concentration was 10ng / mL, the gliclazide concentration was 100μm, and the Rapamycin concentration was 100nM. The addition time of TGF-β1 was as described in Example 5, and Rapamycin and gliclazide were added simultaneously. After 48h incubation, protein was quantified and detected by Western-blot technique.

[0039] Experimental results: As shown in Figure 11, in the co-culture group (TGFβ1 + gliclazide), the expression level of α-SMA protein was significantly decreased compared with the TGFβ1 alone group, and compared with another co-culture group (TGFβ1 + gliclazide + Rapamycin), the expression level of α-SMA protein was significantly increased, and the difference was statistically significant (P<0.05).

[0040] The above embodiments are merely illustrative of the preferred embodiments of the present invention, and are not intended to limit the scope of the present invention. Any modifications and improvements made by those skilled in the art to the technical solutions of the present invention without departing from the design concept of the present invention should be included within the scope of protection defined by the claims of the present invention.

Claims

1. 23. Use of an ion channel blocker in the manufacture of a medicament for treating and / or preventing liver fibrosis.

2. The use according to claim 1, characterized in that the ion channel blocker is a potassium ion channel blocker.

3. The use according to claim 2, characterized in that the potassium ion channel blocker comprises gliclazide.

4. The use according to claim 1, characterized in that the liver fibrosis is caused by CCl 4 The present study included hepatic fibrosis induced by IL-1.

5. Use of gliclazide in the manufacture of a medicine for inhibiting autophagy in liver tissue.

6. 16. Use of gliclazide in the manufacture of a medicament for inhibiting the proliferation of hepatic stellate cells.

7. The use according to claim 6, characterized in that the hepatic stellate cells comprise HSC-T6 cells.

8. Use of gliclazide in the manufacture of a medicament for downregulating hepatocyte α-SMA.

9. Use of gliclazide in the manufacture of a medicament for downregulating hepatocyte LC3.

10. Use of gliclazide in the manufacture of a medicament for upregulating hepatocyte P62.